NASDAQ:KMDA - Kamada Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$4.95 0.00 (0.00 %)
(As of 05/27/2018 05:57 AM ET)
Previous Close$4.95
Today's Range$4.95 - $4.95
52-Week Range$3.75 - $8.61
Volume947 shs
Average Volume18,698 shs
Market Capitalization$199.30 million
P/E Ratio15.97
Dividend YieldN/A
Beta1.17

About Kamada (NASDAQ:KMDA)

Kamada logoKamada Ltd. develops, produces, and markets specialty plasma-derived protein therapeutics. It operates through two segments, Proprietary Products and Distribution. The company offers respiratory products, including Glassia for use in augmentation and maintenance therapy in adults with emphysema due to congenital Alpha-1 Antitrypsin deficiency (AATD). It also provides immunoglobulin products that comprise KamRAB for prophylaxis of rabies disease; KamRho (D) IM to treat prophylaxis of hemolytic disease of newborns; KamRho(D)IV for immune thermobocytopunic purpura; and snake bite antiserum to treat snake bites by the vipera palaestinae and echis coloratus. In addition, the company offers other products, including Heparin Lock Flush to maintain patency of indwelling IV catheter; Kamacaine 0.5% used as anesthesia for surgery, diagnostic, therapeutic, and obstetrical procedures, as well as spinal anesthesia for surgery; and Human Transferrin, which is used as a cultural medium for diagnostic assays and cell cultures. Further, the company distributes respiratory products, including Bramitob to manage chronic pulmonary infection and FOSTER for the treatment of asthma; and immunoglobulins comprising IVIG 5% for the treatment of various immunodeficiency-related conditions; Varitect, a varicella zoster immunoglobulin; Zutectra and Hepatect CP for prevention of hepatitis B virus; and Megalotect, a CMV immunoglobulin. Additionally, it provides Heparin sodium injection to treat thrombo-embolic disorders; and Albumin for maintenance of blood plasma. Kamada Ltd. also offers coagulation factors comprising Factor VIII and Factor IX, as well as IXIARO vaccine. The company markets its products through strategic partners in the United States, as well as through distributors internationally. Kamada Ltd. has strategic partnerships with Baxter International Inc.; Chiesi Farmaceutici; PARI GmbH; and Kedrion S.p.A. The company was founded in 1990 and is headquartered in Rehovot, Israel.

Receive KMDA News and Ratings via Email

Sign-up to receive the latest news and ratings for KMDA and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:KMDA
CUSIPN/A
Phone972-8940-6472

Debt

Debt-to-Equity Ratio0.01
Current Ratio3.47
Quick Ratio2.44

Price-To-Earnings

Trailing P/E Ratio15.97
Forward P/E Ratio18.33
P/E GrowthN/A

Sales & Book Value

Annual Sales$102.82 million
Price / Sales1.94
Cash Flow$0.2584 per share
Price / Cash19.16
Book Value$2.24 per share
Price / Book2.21

Profitability

EPS (Most Recent Fiscal Year)$0.18
Net Income$6.90 million
Net Margins11.17%
Return on Equity14.64%
Return on Assets10.67%

Miscellaneous

Employees377
Outstanding Shares40,260,000

Kamada (NASDAQ:KMDA) Frequently Asked Questions

What is Kamada's stock symbol?

Kamada trades on the NASDAQ under the ticker symbol "KMDA."

How were Kamada's earnings last quarter?

Kamada Ltd. (NASDAQ:KMDA) issued its quarterly earnings data on Tuesday, May, 15th. The biotechnology company reported $0.03 EPS for the quarter, meeting analysts' consensus estimates of $0.03. The biotechnology company had revenue of $17.44 million for the quarter, compared to analyst estimates of $24.89 million. Kamada had a return on equity of 14.64% and a net margin of 11.17%. View Kamada's Earnings History.

When is Kamada's next earnings date?

Kamada is scheduled to release their next quarterly earnings announcement on Tuesday, August, 7th 2018. View Earnings Estimates for Kamada.

What price target have analysts set for KMDA?

3 equities research analysts have issued 12 month target prices for Kamada's stock. Their forecasts range from $7.00 to $7.00. On average, they anticipate Kamada's stock price to reach $7.00 in the next twelve months. View Analyst Ratings for Kamada.

Who are some of Kamada's key competitors?

Who are Kamada's key executives?

Kamada's management team includes the folowing people:
  • Mr. Amir London, Chief Exec. Officer (Age 49)
  • Mr. David Tsur, Co-Founder & Active Deputy Chairman (Age 67)
  • Dr. Liliana Bar, VP of R&D & IP (Age 63)
  • Mr. Chaime Orlev, Chief Financial Officer (Age 48)
  • Mr. Eran Nir, VP of Operations & Plant Mang. (Age 45)

Has Kamada been receiving favorable news coverage?

Press coverage about KMDA stock has been trending somewhat positive this week, Accern reports. Accern ranks the sentiment of press coverage by analyzing more than twenty million blog and news sources. Accern ranks coverage of companies on a scale of negative one to one, with scores nearest to one being the most favorable. Kamada earned a media sentiment score of 0.04 on Accern's scale. They also assigned news headlines about the biotechnology company an impact score of 45.99 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the company's share price in the next few days.

Who are Kamada's major shareholders?

Kamada's stock is owned by a variety of of retail and institutional investors. Top institutional investors include Worth Venture Partners LLC (0.13%) and Worth Venture Partners LLC (0.13%). View Institutional Ownership Trends for Kamada.

Which institutional investors are selling Kamada stock?

KMDA stock was sold by a variety of institutional investors in the last quarter, including Worth Venture Partners LLC and Worth Venture Partners LLC. View Insider Buying and Selling for Kamada.

How do I buy shares of Kamada?

Shares of KMDA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Kamada's stock price today?

One share of KMDA stock can currently be purchased for approximately $4.95.

How big of a company is Kamada?

Kamada has a market capitalization of $199.30 million and generates $102.82 million in revenue each year. The biotechnology company earns $6.90 million in net income (profit) each year or $0.18 on an earnings per share basis. Kamada employs 377 workers across the globe.

How can I contact Kamada?

Kamada's mailing address is 2 HOLTZMAN ST. SCIENCE PARK, REHOVOT L3, 7670402. The biotechnology company can be reached via phone at 972-8940-6472 or via email at [email protected]


MarketBeat Community Rating for Kamada (KMDA)

Community Ranking:  2.3 out of 5 (star star)
Outperform Votes:  137 (Vote Outperform)
Underperform Votes:  162 (Vote Underperform)
Total Votes:  299
MarketBeat's community ratings are surveys of what our community members think about Kamada and other stocks. Vote "Outperform" if you believe KMDA will outperform the S&P 500 over the long term. Vote "Underperform" if you believe KMDA will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Kamada (NASDAQ:KMDA) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
3 Wall Street analysts have issued ratings and price targets for Kamada in the last 12 months. Their average twelve-month price target is $7.00, suggesting that the stock has a possible upside of 41.41%. The high price target for KMDA is $7.00 and the low price target for KMDA is $7.00. There are currently 3 buy ratings for the stock, resulting in a consensus rating of "Buy."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 3.003.003.003.00
Ratings Breakdown: 0 Sell Rating(s)
0 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $7.00$7.00$7.00$8.50
Price Target Upside: 41.41% upside35.92% upside35.92% upside75.26% upside

Kamada (NASDAQ:KMDA) Consensus Price Target History

Price Target History for Kamada (NASDAQ:KMDA)

Kamada (NASDAQ:KMDA) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
2/8/2018HC WainwrightReiterated RatingBuyHighView Rating Details
2/2/2018Chardan CapitalInitiated CoverageBuy ➝ Buy$7.00LowView Rating Details
10/12/2017Jefferies GroupReiterated RatingBuy$7.00N/AView Rating Details
(Data available from 5/27/2016 forward)

Earnings

Kamada (NASDAQ:KMDA) Earnings History and Estimates Chart

Earnings by Quarter for Kamada (NASDAQ:KMDA)

Kamada (NASDAQ:KMDA) Earnings Estimates

2018 EPS Consensus Estimate: $0.27
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20181$0.02$0.02$0.02
Q2 20181$0.09$0.09$0.09
Q3 20181$0.06$0.06$0.06
Q4 20181$0.10$0.10$0.10

Kamada (NASDAQ KMDA) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
8/7/2018        
5/15/20183/31/2018$0.03$0.03$24.89 million$17.44 millionViewListenView Earnings Details
2/7/2018n/a$0.06$0.16$32.90 million$35.71 millionViewN/AView Earnings Details
11/13/2017Q3 2017($0.01)$24.84 million$22.92 millionViewN/AView Earnings Details
8/1/20176/30/2017$0.12$0.13$33.30 million$32.55 millionViewListenView Earnings Details
5/16/20173/31/2017($0.03)($0.11)$20.82 million$11.65 millionViewN/AView Earnings Details
2/6/201712/31/2016($0.04)($0.05)$27.74 million$24.26 millionViewListenView Earnings Details
11/10/20169/30/2016($0.04)($0.03)$20.32 million$19.37 millionViewN/AView Earnings Details
8/2/2016Q216($0.04)($0.04)$18.50 million$19.10 millionViewN/AView Earnings Details
5/9/2016Q1 2016($0.06)($0.06)$15.10 million$14.80 millionViewN/AView Earnings Details
2/2/2016Q415($0.09)$0.03$27.10 million$25.90 millionViewN/AView Earnings Details
11/10/2015Q315($0.04)($0.13)$18.67 million$16.10 millionViewListenView Earnings Details
7/30/2015Q215($0.03)($0.06)$21.82 million$19.20 millionViewListenView Earnings Details
5/12/2015Q115($0.05)($0.15)$16.12 million$9.00 millionViewListenView Earnings Details
2/11/2015Q4$0.01$0.05$24.53 million$25.79 millionViewN/AView Earnings Details
11/12/2014Q314($0.04)($0.09)$19.00 million$17.20 millionViewN/AView Earnings Details
8/14/2014Q214($0.02)($0.23)$17.17 million$15.80 millionViewN/AView Earnings Details
5/8/2014Q114($0.03)($0.09)$15.97 million$13.20 millionViewN/AView Earnings Details
2/5/2014Q413$0.05$0.04$25.22 million$24.40 millionViewN/AView Earnings Details
8/1/2013Q2 2013$0.01$0.03$16.30 million$16.12 millionViewN/AView Earnings Details
5/6/2013Q1 2013($0.03)($0.07)$12.60 millionViewN/AView Earnings Details
3/9/2013Q4 2012($0.03)$0.11ViewN/AView Earnings Details
2/28/2012Q4 2011($0.03)($0.10)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

Kamada (NASDAQ:KMDA) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

Kamada (NASDAQ KMDA) Insider Trading and Institutional Ownership History

Institutional Ownership Percentage: 9.76%
Insider Trading History for Kamada (NASDAQ:KMDA)
Insider Trading History for Kamada (NASDAQ:KMDA)

Kamada (NASDAQ KMDA) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
(Data available from 1/1/2013 forward)

Headlines

Kamada (NASDAQ KMDA) News Headlines

Source:
DateHeadline
$0.07 EPS Expected for Kamada Ltd. (KMDA) This Quarter$0.07 EPS Expected for Kamada Ltd. (KMDA) This Quarter
www.americanbankingnews.com - May 26 at 5:14 PM
Kamada (KMDA) Upgraded at Zacks Investment ResearchKamada (KMDA) Upgraded at Zacks Investment Research
www.americanbankingnews.com - May 18 at 3:07 PM
Jefferies Group Analysts Cut Earnings Estimates for Kamada Ltd. (KMDA)Jefferies Group Analysts Cut Earnings Estimates for Kamada Ltd. (KMDA)
www.americanbankingnews.com - May 18 at 8:41 AM
Kamada (KMDA) Rating Lowered to Strong Sell at ValuEngineKamada (KMDA) Rating Lowered to Strong Sell at ValuEngine
www.americanbankingnews.com - May 17 at 4:51 PM
Brokers Issue Forecasts for Kamada Ltd.s Q2 2018 Earnings (KMDA)Brokers Issue Forecasts for Kamada Ltd.'s Q2 2018 Earnings (KMDA)
www.americanbankingnews.com - May 17 at 6:35 AM
Kamadas (KMDA) CEO Amir London on Q1 2018 Results - Earnings Call TranscriptKamada's (KMDA) CEO Amir London on Q1 2018 Results - Earnings Call Transcript
seekingalpha.com - May 15 at 5:00 PM
Kamada (KMDA) Releases Quarterly  Earnings Results, Meets ExpectationsKamada (KMDA) Releases Quarterly Earnings Results, Meets Expectations
www.americanbankingnews.com - May 15 at 11:59 AM
Kamada beats by $0.01, misses on revenueKamada beats by $0.01, misses on revenue
seekingalpha.com - May 15 at 9:47 AM
Kamada: 1Q Earnings SnapshotKamada: 1Q Earnings Snapshot
finance.yahoo.com - May 15 at 9:47 AM
Kamada Reports Financial Results for First Quarter of 2018Kamada Reports Financial Results for First Quarter of 2018
finance.yahoo.com - May 15 at 9:47 AM
Kamada Ltd to Host Earnings CallKamada Ltd to Host Earnings Call
finance.yahoo.com - May 15 at 9:47 AM
Kamada Ltd. (KMDA) Receives Consensus Rating of "Buy" from BrokeragesKamada Ltd. (KMDA) Receives Consensus Rating of "Buy" from Brokerages
www.americanbankingnews.com - May 13 at 10:13 AM
Kamada (KMDA) Set to Announce Earnings on TuesdayKamada (KMDA) Set to Announce Earnings on Tuesday
www.americanbankingnews.com - May 11 at 11:17 AM
Zacks: Brokerages Expect Kamada Ltd. (KMDA) Will Post Quarterly Sales of $24.89 MillionZacks: Brokerages Expect Kamada Ltd. (KMDA) Will Post Quarterly Sales of $24.89 Million
www.americanbankingnews.com - May 11 at 2:38 AM
 Analysts Anticipate Kamada Ltd. (KMDA) Will Announce Earnings of $0.03 Per Share Analysts Anticipate Kamada Ltd. (KMDA) Will Announce Earnings of $0.03 Per Share
www.americanbankingnews.com - May 9 at 3:04 PM
Kamada to Announce First Quarter 2018 Financial Results and Host Conference Call on May 15Kamada to Announce First Quarter 2018 Financial Results and Host Conference Call on May 15
finance.yahoo.com - May 9 at 9:20 AM
Kedrion Biopharma and Kamada Announce KEDRAB® (Rabies Immune Globulin ) Now Shipping; Distribution Timed to Meet Spring/Summer Demand for ProductKedrion Biopharma and Kamada Announce KEDRAB® (Rabies Immune Globulin ) Now Shipping; Distribution Timed to Meet Spring/Summer Demand for Product
finance.yahoo.com - May 8 at 9:13 AM
Israel-based Medical Cannabis Solutions Provider, Kanabo Research, has Signed an Agreement With Constance Therapeutics From the USIsrael-based Medical Cannabis Solutions Provider, Kanabo Research, has Signed an Agreement With Constance Therapeutics From the US
finance.yahoo.com - April 25 at 9:20 AM
Kamada (KMDA) Says FDA has Continued Concerns and Questions Related to Safety Profile of Inhaled AATKamada (KMDA) Says FDA has Continued Concerns and Questions Related to Safety Profile of Inhaled AAT
www.streetinsider.com - April 24 at 9:15 AM
Here’s What Just Happened With Prothena And KamadaHere’s What Just Happened With Prothena And Kamada
finance.yahoo.com - April 24 at 9:15 AM
Zacks: Analysts Anticipate Kamada Ltd. (KMDA) Will Post Quarterly Sales of $24.89 MillionZacks: Analysts Anticipate Kamada Ltd. (KMDA) Will Post Quarterly Sales of $24.89 Million
www.americanbankingnews.com - April 24 at 4:26 AM
Kamada still not there with Phase 3 protocol for inhaled AAT therapyKamada still not there with Phase 3 protocol for inhaled AAT therapy
seekingalpha.com - April 23 at 4:33 PM
BRIEF-Kamada Gets Feedback From FDA On Proposed Phase 3 Protocol For Inhaled Alpha-1-AntitrypsinBRIEF-Kamada Gets Feedback From FDA On Proposed Phase 3 Protocol For Inhaled Alpha-1-Antitrypsin
www.reuters.com - April 23 at 9:02 AM
Kamada Received Feedback from FDA on Proposed Phase 3 Protocol for Inhaled Alpha-1-Antitrypsin for Treatment of Alpha-1 Antitrypsin Deficiency DiseaseKamada Received Feedback from FDA on Proposed Phase 3 Protocol for Inhaled Alpha-1-Antitrypsin for Treatment of Alpha-1 Antitrypsin Deficiency Disease
finance.yahoo.com - April 23 at 9:02 AM
Kamada shares drop on FDAs continued concerns about therapys safety, trial delayKamada shares drop on FDA's continued concerns about therapy's safety, trial delay
finance.yahoo.com - April 23 at 9:02 AM
 Brokerages Anticipate Kamada Ltd (KMDA) Will Announce Earnings of $0.03 Per Share Brokerages Anticipate Kamada Ltd (KMDA) Will Announce Earnings of $0.03 Per Share
www.americanbankingnews.com - April 22 at 7:34 AM
Kamada Ltd (KMDA) Given Average Rating of "Buy" by AnalystsKamada Ltd (KMDA) Given Average Rating of "Buy" by Analysts
www.americanbankingnews.com - April 18 at 9:03 AM
Zacks Investment Research Lowers Kamada (KMDA) to SellZacks Investment Research Lowers Kamada (KMDA) to Sell
www.americanbankingnews.com - April 17 at 9:49 PM
Kamada (KMDA) Downgraded to D+ at TheStreetKamada (KMDA) Downgraded to D+ at TheStreet
www.americanbankingnews.com - April 13 at 7:51 PM
Kamada (KMDA) Lowered to "Sell" at Zacks Investment ResearchKamada (KMDA) Lowered to "Sell" at Zacks Investment Research
www.americanbankingnews.com - April 13 at 1:35 PM
Kamada (KMDA) Stock Rating Upgraded by Zacks Investment ResearchKamada (KMDA) Stock Rating Upgraded by Zacks Investment Research
www.americanbankingnews.com - April 10 at 1:10 PM
Zacks Investment Research Downgrades Kamada (KMDA) to SellZacks Investment Research Downgrades Kamada (KMDA) to Sell
www.americanbankingnews.com - April 7 at 7:46 PM
$24.89 Million in Sales Expected for Kamada Ltd (KMDA) This Quarter$24.89 Million in Sales Expected for Kamada Ltd (KMDA) This Quarter
www.americanbankingnews.com - April 7 at 4:23 AM
$0.03 EPS Expected for Kamada Ltd (KMDA) This Quarter$0.03 EPS Expected for Kamada Ltd (KMDA) This Quarter
www.americanbankingnews.com - April 5 at 10:10 AM
Kamada Ltd (KMDA) Receives Average Rating of "Buy" from AnalystsKamada Ltd (KMDA) Receives Average Rating of "Buy" from Analysts
www.americanbankingnews.com - March 24 at 8:28 AM
Kamada Ltd (KMDA) Expected to Post Quarterly Sales of $24.89 MillionKamada Ltd (KMDA) Expected to Post Quarterly Sales of $24.89 Million
www.americanbankingnews.com - March 21 at 5:56 AM
Kamada (KMDA) Stock Rating Upgraded by ValuEngineKamada (KMDA) Stock Rating Upgraded by ValuEngine
www.americanbankingnews.com - March 19 at 11:16 PM
Zacks: Analysts Expect Kamada Ltd (KMDA) to Announce $0.03 Earnings Per ShareZacks: Analysts Expect Kamada Ltd (KMDA) to Announce $0.03 Earnings Per Share
www.americanbankingnews.com - March 19 at 5:12 AM
Kamada (KMDA) Upgraded at ValuEngineKamada (KMDA) Upgraded at ValuEngine
www.americanbankingnews.com - March 18 at 10:28 PM
Kamada (KMDA) Cut to Sell at ValuEngineKamada (KMDA) Cut to Sell at ValuEngine
www.americanbankingnews.com - March 18 at 7:42 PM
Kamada (KMDA) Lowered to "Sell" at ValuEngineKamada (KMDA) Lowered to "Sell" at ValuEngine
www.americanbankingnews.com - March 4 at 3:54 PM
Zacks: Analysts Anticipate Kamada Ltd (KMDA) to Announce $0.03 Earnings Per ShareZacks: Analysts Anticipate Kamada Ltd (KMDA) to Announce $0.03 Earnings Per Share
www.americanbankingnews.com - March 2 at 5:12 AM
Kamada Ltd (KMDA) Receives Consensus Rating of "Buy" from AnalystsKamada Ltd (KMDA) Receives Consensus Rating of "Buy" from Analysts
www.americanbankingnews.com - February 27 at 10:12 AM
Kamada (KMDA) Upgraded at TheStreetKamada (KMDA) Upgraded at TheStreet
www.americanbankingnews.com - February 18 at 9:22 PM
Zacks: Brokerages Anticipate Kamada Ltd (KMDA) to Post $0.03 Earnings Per ShareZacks: Brokerages Anticipate Kamada Ltd (KMDA) to Post $0.03 Earnings Per Share
www.americanbankingnews.com - February 13 at 11:14 AM
Jefferies Group Weighs in on Kamada Ltds Q1 2018 Earnings (KMDA)Jefferies Group Weighs in on Kamada Ltd's Q1 2018 Earnings (KMDA)
www.americanbankingnews.com - February 12 at 2:20 AM
Kamada (KMDA) Rating Increased to Hold at Zacks Investment ResearchKamada (KMDA) Rating Increased to Hold at Zacks Investment Research
www.americanbankingnews.com - February 11 at 9:36 AM
Research Analysts Offer Predictions for Kamada Ltds Q3 2018 Earnings (KMDA)Research Analysts Offer Predictions for Kamada Ltd's Q3 2018 Earnings (KMDA)
www.americanbankingnews.com - February 9 at 11:37 AM
Kamada (KMDA) Upgraded to "Hold" at ValuEngineKamada (KMDA) Upgraded to "Hold" at ValuEngine
www.americanbankingnews.com - February 8 at 10:34 PM
Kamada (KMDA) Announces  Earnings ResultsKamada (KMDA) Announces Earnings Results
www.americanbankingnews.com - February 8 at 10:32 AM

SEC Filings

Kamada (NASDAQ:KMDA) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Kamada (NASDAQ:KMDA) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Kamada (NASDAQ KMDA) Stock Chart for Sunday, May, 27, 2018

Loading chart…

This page was last updated on 5/27/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.